Myelofibrosis

Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that socio-racial characteristics may have on outcomes of patients with primary myelofibrosis.

The FDA granted fast track designation to two oncology therapies.

In this video, Ruben Mesa, MD, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.

In this video, Ruben Mesa, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

In this video, Ruben Mesa, MD, discussed a study he presented at ASCO Annual Meeting examining the impact of transfusion burden on quality of life and functioning on patients with myelofibrosis.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, that looked an ALK2 inhibitor along with ruxolitinib in the treatment of anemia in myelofibrosis.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, examining the use of luspatercept in the treatment of anemia in myelofibrosis patients.

In this video, Idoroenyi Amanam, MD, discussed a study presented at ASCO Annual Meeting, examining the treatment of anemia in myelofibrosis patients.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind an abstract presented at ASCO Annual Meeting, examining a new compound directly targeting the ACVR1 gene in order to improve anemia in patients with myelofibrosis.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study he presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.